Siren L.L.C. Buys 247,347 Shares of Stoke Therapeutics, Inc. $STOK

Key Points

• Siren L.L.C. increased its stake in Stoke Therapeutics by 12.4%, acquiring an additional 247,347 shares, bringing its total ownership to 2,247,347 shares valued at approximately $14.95 million.
• Stoke Therapeutics reported earnings per share of ($0.40), beating analysts' expectations, and had a revenue of $13.82 million for the quarter.
• Analysts have given Stoke Therapeutics a consensus rating of “Buy”, with a target price averaging $25.57, reflecting optimism about the stock's potential growth.

Siren L.L.C. boosted its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,247,347 shares of the company's stock after purchasing an additional 247,347 shares during the quarter. Stoke Therapeutics makes up 0.9% of Siren L.L.C.'s investment portfolio, making the stock its 29th largest position. Siren L.L.C. owned about 4.12% of Stoke Therapeutics worth $14,945,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC raised its holdings in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $72,000. US Bancorp DE raised its holdings in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after acquiring an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $92,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $107,000.

Stoke Therapeutics Trading Up 2.7%

Shares of NASDAQ STOK opened at $22.66 on Thursday. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 26.66 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $22.79. The stock's 50-day moving average is $15.56 and its 200 day moving average is $11.31.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. On average, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 14,922 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total transaction of $300,529.08. Following the transaction, the general counsel directly owned 18,176 shares in the company, valued at $366,064.64. This trade represents a 45.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 5,501 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total value of $109,304.87. Following the transaction, the insider owned 18,469 shares in the company, valued at approximately $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,719 shares of company stock worth $2,063,359 in the last ninety days. 9.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on STOK shares. Jefferies Financial Group started coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 price target on the stock. HC Wainwright lowered their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Finally, Wedbush raised their price objective on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.